The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

Heller, S; Bowering, K; Raskin, P; Liebl, A; Buchholtz, K; Gorst-Rasmussen, A; Pieber, T R.

Affiliation

Heller S; Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.
Bowering K; Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Raskin P; University of Texas Southwestern Medical Center, Dallas, TX, USA.
Liebl A; Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany.
Buchholtz K; Novo Nordisk A/S, Søborg, Denmark.
Gorst-Rasmussen A; Novo Nordisk A/S, Søborg, Denmark.
Pieber TR; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.

Diabet Med ; 2018 May 26.

Article in En | MEDLINE | ID: mdl-29802636

Full text: 1 Database: MEDLINE Type of study: Clinical_trials Language: En Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Type of study: Clinical_trials Language: En Year: 2018 Type: Article